Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Nature Clinical Practice Gastroenterology &Hepatology

• Publication date

  2006-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ncpgasthep0447PMID 16582964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease

  2006cited by this paper
• A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator.

  2005cited by this paper
• New Concepts in the Pathophysiology of Inflammatory Bowel Disease

  2005cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Maintenance of Remission over 1 Year in Patients with Active Crohnʼs Disease Treated with Adalimumab: Results of a Blinded, Placebo-Controlled Study

  2005cited by this paper
• Remission and Clinical Response Induced and Maintained in Patients with Active Crohnʼs Disease Treated for 1-Year Open-Label with Adalimumab: 858

  2005cited by this paper
• Soluble tumor necrosis factor (TNF) receptor‐1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor‐β1

  2005cited by this paper
• Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1.

  2005cited by this paper
• Alleviation of polyarticular syndrome in multicentric reticulohistiocytosis with intravenous zoledronate

  2005cited by this paper
• Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

  2005cited by this paper
• Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.

  2005cited by this paper
• Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution.

  2005cited by this paper
• Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials

  2005cited by this paper
• A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.

  2005cited by this paper
• Effect of the Anti-TNF Agents, Adalimumab, Etanercept, Infliximab, and Certolizumab PEGOL (CDP870) on the Induction of Apoptosis in Activated Peripheral Blood Lymphocytes and Monocytes: 806

  2005cited by this paper
• NOD2 and Crohn's disease: loss or gain of function?

  2005cited by this paper
• A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease

  2004cited by this paper
• Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.

  2004cited by this paper
• Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis

  2004cited by this paper
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  2004cited by this paper
• Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

  2004cited by this paper
• CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

  2004cited by this paper
• Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone

  2004cited by this paper
• Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

  2004cited by this paper
• Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

  2004cited by this paper
• Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis

  2004cited by this paper
• The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

  2004cited by this paper
• Pneumocystis carinii Pneumonia During Maintenance Anti–Tumor Necrosis Factor-&agr; Therapy with Infliximab for Crohn’s Disease

  2004cited by this paper
• Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist

  2003cited by this paper
• Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

  2003cited by this paper
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

  2003cited by this paper
• The immunological and genetic basis of inflammatory bowel disease

  2003cited by this paper
• Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot study

  2003cited by this paper
• The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience

  2003cited by this paper
• Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

  2003cited by this paper
• Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

  2003cited by this paper
• Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

  2003cited by this paper
• Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

  2002cited by this paper
• Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells.

  2002cited by this paper
• Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

  2002cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

  2001cited by this paper
• An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.

  2001cited by this paper
• Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Invasive pulmonary aspergillosis associated with infliximab therapy.

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.

  2001cited by this paper
• Role of cytokines in the pathogenesis of inflammatory bowel disease.

  2000cited by this paper
• Tumor necrosis factor: biology and therapeutic inhibitors.

  2000cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Infliximab for the treatment of fistulas in patients with Crohn's disease.

  1999cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

  1997cited by this paper
• Tumour necrosis factor alpha in stool as a marker of intestinal inflammation.

  1992cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Validation of a de‐immunization strategy for monoclonal antibodies using cynomolgus macaque as a surrogate for human

  2020cites this paper
• Antitumor evaluation of carboxymethyl chitosan based norcantharidin conjugates against gastric cancer as novel polymer therapeutics.

  2019cites this paper
• TARGETING THE MALIGNANT B CELL MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

  2019cites this paper
• Engineering Symbiotic Microbiota for in Situ Delivery of Therapeutic Proteins

  2018cites this paper
• Chapter 28 – Cardiac Immunomodulation

  2017cites this paper
• Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

  2017cites this paper
• Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties

  2016cites this paper
• Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

  2014cites this paper
• Adverse effects of golimumab in the treatment of rheumatologic diseases

  2014cites this paper
• Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review

  2014influential citation
• Paraoxonase-1 Suppresses Experimental Colitis via the Inhibition of IFN-γ Production from CD4 T Cells

  2013cites this paper
• Colitis via the Inhibition of IFN-Paraoxonase-1 Suppresses Experimental

  2013cites this paper
• Paraoxonase-1 Suppresses Experimental Colitis via the Inhibition of IFN-g Production from CD4 T Cells

  2013cites this paper
• Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy.

  2012cites this paper
• Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.

  2012cites this paper
• Early Versus Late Surgery in Patients With Intestinal Behçet Disease

  2012cites this paper
• Orofacial granulomatosis as first manifestation of Crohn's disease: successful treatment of both conditions with a combination of infliximab and dapsone.

  2012cites this paper
• Fc Gamma Receptor CD64 Modulates the Inhibitory Activity of Infliximab

  2012cites this paper
• Apoptosis as a Mechanism of Action of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis

  2012cites this paper
• Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

  2011cites this paper
• Comparative analysis of the effects of anti‐IL‐6 receptor mAb and anti‐TNF mAb treatment on CD4+ T‐cell responses in murine colitis

  2011influential citation
• Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit.

  2011cites this paper
• A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

  2011cites this paper
• Pain from Abdominal Organs

  2010cites this paper
• [Bronchopulmonary lesions in chronic inflammatory bowel diseases].

  2010cites this paper
• Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α

  2010cites this paper
• Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update

  2010cites this paper
• Herstellung und Charakterisierung von rekombinanten, ETA-basierten CD64-Immuntoxinen zur Bekämpfung von dysregulierten Makrophagen bei chronischen Hautentzündungen

  2010cites this paper
• Evidence-Based Chronic Pain Management

  2010influential citation
• Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen.

  2009cites this paper
• Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone

  2009cites this paper
• Managing Crohn Disease in Children and Adolescents

  2008cites this paper
• Certolizumab pegol

  2008cites this paper
• Production systems for recombinant antibodies.

  2008cites this paper
• Managing Crohn disease in children and adolescents : focus on tumor necrosis factor antagonists.

  2008cites this paper
• Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus.

  2008cites this paper
• Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus

  2008cites this paper
• Therapy Insight: how the gut talks to the joints—inflammatory bowel disease and the spondyloarthropathies

  2007cites this paper
• Fatal miliary Coccidioidomycosis in a patient receiving infliximab therapy: a case report

  2007cites this paper
• Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)

  2007cites this paper
• Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease

  2007cites this paper
• Adalimumab in patients with Crohn’s disease – safety and efficacy in an open‐label single centre study

  2007cites this paper
• Treatment with biologic therapies and the risk of cancer in patients with IBD

  2007cites this paper
• Current and future therapies for inflammatory bowel disease

  2007cites this paper
• Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.

  2007cites this paper
• The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model.

  2007cites this paper
• Effects of tumour necrosis factor-alpha on human sperm motility and apoptosis.

  2007cites this paper
• Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes.

  2007cites this paper
• Late‐breaking news from the “4th International Meeting on Inflammatory Bowel Diseases” Capri, 2006

  2007cites this paper
• Medical Management of Crohn's Disease in 2006: What's on the Horizon?

  2007cites this paper
• Infliximab: a novel treatment option for refractory orofacial granulomatosis.

  2007cites this paper
• Effects of Tumour Necrosis Factor-α on Human Sperm Motility and Apoptosis

  2007cites this paper
• Tumor necrosis factor-a inhibition and palmoplantar pustulosis: Janus-faced therapy?

  2007cites this paper
• Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases

  2007cites this paper
• Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet.

  2007cites this paper
• 37 - Drugs that act on the immune system: Cytokines and monoclonal antibodies

  2007cites this paper
• Behandling med TNF α antistoffet infliksimab (Remicade) ved inflammatorisk tarmsykdom, indikasjon og effekt. Gjennomgang av et pasientmateriale i tidsrommet 2001- 2006 ved Gastromedisinsk avdeling Ullevål universitetssykehus

  2007cites this paper
• Interleukin-6 trans-signaling in inflammatory bowel disease.

  2006cites this paper
• Drug Therapy of Inflammatory Bowel Disease in Fertile Women

  2006cites this paper